GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ThermoGenesis Holdings Inc (STU:THR) » Definitions » PB Ratio

ThermoGenesis Holdings (STU:THR) PB Ratio : 4.65 (As of May. 25, 2024)


View and export this data going back to . Start your Free Trial

What is ThermoGenesis Holdings PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-25), ThermoGenesis Holdings's share price is €0.525. ThermoGenesis Holdings's Book Value per Share for the quarter that ended in Mar. 2024 was €0.11. Hence, ThermoGenesis Holdings's PB Ratio of today is 4.65.

The historical rank and industry rank for ThermoGenesis Holdings's PB Ratio or its related term are showing as below:

STU:THR' s PB Ratio Range Over the Past 10 Years
Min: 0.15   Med: 1.07   Max: 37.6
Current: 5.03

During the past 13 years, ThermoGenesis Holdings's highest PB Ratio was 37.60. The lowest was 0.15. And the median was 1.07.

STU:THR's PB Ratio is ranked worse than
79.37% of 790 companies
in the Medical Devices & Instruments industry
Industry Median: 2.23 vs STU:THR: 5.03

During the past 12 months, ThermoGenesis Holdings's average Book Value Per Share Growth Rate was -96.90% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of ThermoGenesis Holdings was 41.70% per year. The lowest was -89.20% per year. And the median was -4.00% per year.

Back to Basics: PB Ratio


ThermoGenesis Holdings PB Ratio Historical Data

The historical data trend for ThermoGenesis Holdings's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ThermoGenesis Holdings PB Ratio Chart

ThermoGenesis Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.32 3.11 3.16 0.78 -

ThermoGenesis Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 0.78 0.92 - 5.49

Competitive Comparison of ThermoGenesis Holdings's PB Ratio

For the Medical Devices subindustry, ThermoGenesis Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ThermoGenesis Holdings's PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ThermoGenesis Holdings's PB Ratio distribution charts can be found below:

* The bar in red indicates where ThermoGenesis Holdings's PB Ratio falls into.



ThermoGenesis Holdings PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

ThermoGenesis Holdings's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=0.525/0.113
=4.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


ThermoGenesis Holdings  (STU:THR) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


ThermoGenesis Holdings PB Ratio Related Terms

Thank you for viewing the detailed overview of ThermoGenesis Holdings's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ThermoGenesis Holdings (STU:THR) Business Description

Traded in Other Exchanges
Address
2711 Citrus Road, Rancho Cordova, CA, USA, 95742
ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.